Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: A comprehensive review

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.3, 2012, Pages 8-12

  Shiotani, Akiko ^a   Manabe, Noriaki ^a   Kamada, Tomoari ^a   Fujimura, Yoshinori ^b   Sakakibara, Takashi ^b   Haruma, Ken ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

Author keywords

1b; Angiotensin type 1 receptor blocker; Angiotensinogen; Aspirin; Interleukin 1 ; Polymorphism; SLCO1B; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; WARFARIN;

CARDIOVASCULAR RISK; DIGESTIVE SYSTEM INJURY; ERADICATION THERAPY; GASTRODUODENAL INJURY; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPPER GASTROINTESTINAL BLEEDING;

EID: 84859400569     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07071.x     Document Type: Review

References (63)

1. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-16.
2. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin: what's the risk? Aliment. Pharmacol. Ther. 2006; 24: 897-908.
3. Sakamoto C, Sugano K, Ota S etal. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur. J. Clin. Pharmacol. 2006; 62: 765-72.
4. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
5. Lanas A, Bajador E, Serrano P etal. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 2000; 343: 834-9.
6. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther. 2002; 16: 1945-53.
7. Hallas J, Dall M, Andries A etal. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726-30.
8. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-73.
9. Shiotani A, Nishi R, Yamanaka Y etal. Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Dig. Dis. Sci. 2011; 56: 465-71.
10. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
11. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol. 2006; 4: 130-42.
12. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 2005; 21: 1411-18.
13. Shiotani A, Sakakibara T, Yamanaka Y etal. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J. Gastroenterol. 2009; 44: 126-31.
14. Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J. Gastroenterol. 2008; 43: 581-8.
15. Weil J, Colin-Jones D, Langman M etal. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
17. Lanas A, Garcia-Rodriguez LA, Arroyo MT etal. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.
18. Chan FK, Chung SC, Suen BY etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001; 344: 967-73.
19. Lai KC, Lam SK, Chu KM etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033-8.
20. Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 285: G414-23.
21. Bregonzio C, Armando I, Ando H etal. AT1 receptor blockade prevents gastric ulcers during cold-restraint stress. Ann. N. Y. Acad. Sci. 2004; 1018: 351-5.
22. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
23. Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am. J. Physiol. 1987; 253: H699-703.
24. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109: 1173-80.
25. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994; 35: 909-15.
26. Scalia R, Gooszen ME, Jones SP etal. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001; 103: 2598-603.
27. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C etal. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J. Hypertens. 2002; 20: 429-37.
28. Tariq M, Khan HA, Elfaki I etal. Gastric antisecretory and antiulcer effects of simvastatin in rats. J. Gastroenterol. Hepatol. 2007; 22: 2316-23.
29. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
30. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther. 2003; 73: 122-30.
31. Fujiwara T, Ikeda M, Esumi K etal. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. 2007; 7: 395-403.
32. Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med. Clin. North Am. 2002; 86: 1447-66, viii.
33. van Oijen MG, Laheij RJ, Koetsier M etal. Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig. Dis. Sci. 2006; 51: 2348-52.
34. Arisawa T, Tahara T, Shibata T etal. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int. J. Mol. Med. 2007; 20: 373-8.
35. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9: 341-9.
36. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001; 61: 3566-9.
37. Pilotto A, Seripa D, Franceschi M etal. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133: 465-71.
38. Martinez C, Blanco G, Ladero JM etal. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 2004; 141: 205-8.
39. van Oijen MG, Huybers S, Peters WH etal. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. Br. J. Clin. Pharmacol. 2005; 60: 623-8.
40. Saeki M, Saito Y, Jinno H etal. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab. Pharmacokinet. 2005; 20: 85-90.
41. Takahashi H, Kashima T, Nomizo Y etal. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 1998; 63: 519-28.
42. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001; 40: 587-603.
43. Vonkeman HE, van de Laar MA, van der Palen J, Brouwers JR, Vermes I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther. 2006; 28: 1670-6.
44. Garcia-Gonzalez MA, Savelkoul PH, Benito R etal. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int. J. Immunogenet. 2005; 32: 299-306.
45. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92-105.
46. El-Omar EM, Carrington M, Chow WH etal. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
47. Garcia-Gonzalez MA, Lanas A, Santolaria S, Crusius JB, Serrano MT, Pena AS. The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. Clin. Exp. Immunol. 2001; 125: 368-75.
48. Shiotani A, Yamaoka Y, El-Zimaity HM, Saeed MA, Qureshi WA, Graham DY. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig. Dis. Sci. 2002; 47: 38-43.
49. Kobashi G, Hata A, Ohta K etal. A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. J. Hum. Genet. 2004; 49: 182-6.
50. Ishigami T, Tamura K, Fujita T etal. Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I. Hypertension 1999; 34: 430-4.
51. Yanai K, Nibu Y, Murakami K, Fukamizu A. A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J. Biol. Chem. 1996; 271: 15981-6.
52. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A. Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension 1999; 33: 108-15.
53. Niemi M, Schaeffeler E, Lang T etal. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-40.
54. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 2005; 15: 513-22.
55. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 2008; 23: 223-35.
56. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 2001; 276: 35669-75.
57. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2003; 304: 223-8.
58. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 2005; 33: 434-9.
59. Nishizato Y, Ieiri I, Suzuki H etal. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003; 73: 554-65.
60. Niemi M, Neuvonen PJ, Hofmann U etal. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 2005; 15: 303-9.
61. Link E, Parish S, Armitage J etal. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N. Engl. J. Med. 2008; 359: 789-99.
62. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 2004; 75: 415-21.
63. Shiotani A, Murao T, Sakakibara T etal. Association of SLCO1B1*1b with peptic ulcer amongst Japanese patients taking low-dose aspirin. Dig. Liver Dis. 2012; 44: 201-5.